CypH 11
Alternative Names: Cmetglo; CypH-11Latest Information Update: 07 Feb 2025
At a glance
- Originator Molecular Targeting Technologies
- Class Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer; Peritoneal cancer
Most Recent Events
- 12 Sep 2024 Preclinical trials in Colorectal cancer (Diagnosis) in USA (Topical), prior to September 2024
- 12 Sep 2024 Preclinical trials in Peritoneal cancer (Diagnosis) in USA (Topical), prior to September 2024
- 12 Sep 2024 Molecular Targeting Technologies plans a phase I trial for Colorectal cancer (Diagnosis) and Peritoneal cancer (Diagnosis) (Topical, Spray)in Q3 2025 (Molecular Targeting Technologies pipeline, September 2024)